Hazlett, Burt & Watson’s Biogen BIIB Stock Holding History

Hazlett, Burt & Watson’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10	Closed	-$1K	–	918
2025 Q3	$1K	Hold	10	–	–	﹤0.01%	836
2025 Q2	$1K	Buy	+10	New	+$1.25K	﹤0.01%	751
2024 Q4	–	Sell	-37	Closed	-$7K	–	751
2024 Q3	$7K	Buy	+37	New	+$7.74K	﹤0.01%	554
2023 Q4	–	Sell	-35	Closed	-$9K	–	683
2023 Q3	$9K	Buy	35 +25	+250%	+$6.69K	0.01%	503
2023 Q2	$3K	Hold	10	–	–	﹤0.01%	586
2023 Q1	$3K	Buy	+10	New	+$2.77K	﹤0.01%	544

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hazlett, Burt & Watson's BIIB Position: Q4 2025 in Review

Hazlett, Burt & Watson sold out of Biogen (BIIB) in Q4 2025, closing a stake of 10 shares — an estimated $1K sold.

Hazlett, Burt & Watson first reported a position in BIIB in Q1 2023 and held it in 6 quarters. The position peaked at $9K in Q3 2023. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

Hazlett, Burt & Watson reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
Hazlett, Burt & Watson sold 10 Biogen shares in Q4 2025, an estimated $1K.
Hazlett, Burt & Watson first reported a position in Biogen in Q1 2023 and held it in 6 quarters.
Hazlett, Burt & Watson's Biogen position peaked at $9K in Q3 2023.
1,001 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Hazlett, Burt & Watson's 13F filing for Q4 2025, filed 10 Feb 2026.